TauRx Raises Additional USD119M in Funding

TauRx Prescription drugs, an Aberdeen, UK- and Singapore-based corporate world chief in tau-based analysis in Alzheimer’s illness (AD), raised USD119M in investment.

The backers weren’t disclosed.

The corporate intends to make use of the budget to boost up construction plans for regulatory approval in China.

Led via Glenn Corr, Leader Working Officer and Leader Industry Officer, TauRx Prescription drugs has devoted the previous 20 years to creating therapies and diagnostics for Alzheimer’s and different neurodegenerative illnesses because of protein aggregation pathology. Pathological aggregation of Tau correlates with medical illness severity and mind atrophy.

The corporate plans to put up HMTM for regulatory approval in the United Kingdom, US and Canada in 2023, with different territories to apply, in step with its total plans to commercialise HMTM and pursue medical trials in different comparable neurodegenerative illnesses.

The certain consequence of this investment spherical, with greater than 99% of warrants exercised, was once prompted via the announcement of Section 3 LUCIDITY (NCT03446001) topline information and provides to USD64 million raised in 2021 thru a prior rights factor.

The TauRx crew of businesses was once established in 2002 in Singapore, proceeding a partnership with the College of Aberdeen, with number one analysis amenities and operation founded in Aberdeen, UK.



Leave a Comment